(Q43949330)

28 November 2017

Antipyrine metabolite formation and excretion in patients with chronic renal failure (English)

1 reference

28 November 2017

M W Teunissen

1

1 reference

28 November 2017

D Kampf

2

1 reference

28 November 2017

I Roots

3

1 reference

28 November 2017

N P Vermeulen

4

1 reference

28 November 2017

D D Breimer

5

1 reference

28 November 2017

1 January 1985

1 reference

European Journal of Clinical Pharmacology

28 November 2017

1 reference

28 November 2017

28

1 reference

28 November 2017

5

1 reference

28 November 2017

589-595

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00544072

28 November 2017

0 references

cites work

Differential effects of enzyme induction on antipyrine metabolite formation

1 reference

12 December 2020

Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

1 reference

12 December 2020

Urinary excretion of D-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function

1 reference

12 December 2020

The metabolism of antipyrine in patients with chronic renal failure

1 reference

12 December 2020

Drug dosage in renal disease

1 reference

12 December 2020

3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance

1 reference

12 December 2020

Interindividual variations in drug disposition. Clinical implications and methods of investigation

1 reference

12 December 2020

Drug metabolites in renal failure: pharmacokinetic and clinical implications

1 reference

12 December 2020

Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis

1 reference

12 December 2020

Salivary Antipyrine Kinetics in Hepatic and Renal Disease and in Patients on Anticonvulsant Therapy

1 reference

12 December 2020

Differential induction of antipyrine metabolism by rifampicin.

1 reference

12 December 2020

Assay of Antipyrine and Its Primary Metabolites in Plasma, Saliva and Urine by High-Performance Liquid Chromatography and Some Preliminary Results in Man

1 reference

12 December 2020

[Demonstration of a new reactive metabolite in metabolism of phenazone (antipyrine)]

1 reference

12 December 2020

Studies on the Different Metabolic Pathways of Antipyrine in Rats: Influence of Phenobarbital and 3-Methylcholanthrene Treatment

1 reference

12 December 2020

Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivo

1 reference

12 December 2020

Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics

1 reference

12 December 2020

The plasma half-life of antipyrine in chromic uraemic and normal subjects

1 reference

12 December 2020

Enhanced drug metabolism and renal dysfunction

1 reference

12 December 2020

Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine

1 reference

12 December 2020

Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time

1 reference

12 December 2020

Metabolism of Drugs. LXX. Further Study on Antipyrine Metabolism

1 reference

12 December 2020

Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review

1 reference

12 December 2020

Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking

1 reference

12 December 2020

Uremia and the liver. II. Drugs and the liver in the uremic patient

1 reference

12 December 2020

The biotransformation of drugs in renal failure

1 reference

12 December 2020

Genetic and environmental factors affecting drug disposition in man

1 reference

12 December 2020

Noncompartmental Determination of the Steady‐State Volume of Distribution

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00544072

1 reference

28 November 2017

1 reference